<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066768</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01440</org_study_id>
    <secondary_id>5889</secondary_id>
    <secondary_id>CDR0000318808</secondary_id>
    <secondary_id>NCI-5889</secondary_id>
    <secondary_id>OSU-0238</secondary_id>
    <secondary_id>2003C0022</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00066768</nct_id>
  </id_info>
  <brief_title>Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Pilot Study of Low Dose Suramin as Modulator of Docetaxel and Gemcitabine in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase I trial is studying the side effects and best dose of suramin when&#xD;
      given together with either docetaxel or gemcitabine in treating patients with stage IIIB or&#xD;
      stage IV non-small cell lung cancer that is refractory to platinum chemotherapy (such as&#xD;
      cisplatin, carboplatin, or oxaliplatin). Drugs used in chemotherapy such as docetaxel and&#xD;
      gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
      Some tumors become resistant to chemotherapy drugs. Combining suramin with either docetaxel&#xD;
      or gemcitabine may reduce resistance to the drugs and kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety of low-dose suramin administered with docetaxel or gemcitabine in&#xD;
      patients with stage IIIB or IV platinum-refractory non-small cell lung cancer.&#xD;
&#xD;
      II. Determine, preliminarily, the antitumor activity of these regimens in these patients.&#xD;
&#xD;
      III. Determine whether suramin plasma concentrations in combination with docetaxel or&#xD;
      gemcitabine can be predicted by pretreatment dose calculations based on clinical parameters.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot, dose-finding study. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
      ARM I: Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on&#xD;
      day 1.&#xD;
&#xD;
      ARM II: Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30&#xD;
      minutes on days 1 and 8.&#xD;
&#xD;
      In both arms, treatment repeats every 3 weeks for 3 courses in the absence of unacceptable&#xD;
      toxicity. Patients with complete or partial response after the initial 3 courses optionally&#xD;
      continue the same therapy for 3 additional courses. Patients with disease progression after 6&#xD;
      courses of treatment on the original arm may cross over and receive treatment on the other&#xD;
      arm. Patients with progressive disease or stable disease after the initial 3 courses cross&#xD;
      over to the other arm and receive treatment on that arm for 3 additional courses. Patients&#xD;
      with responsive or stable disease after the sixth course may continue therapy on that arm.&#xD;
&#xD;
      Cohorts of 6-12 patients in each arm receive doses of suramin calculated from a clinical&#xD;
      formula validated in prior clinical trials. Adjustments on the suramin dose are performed if&#xD;
      the initial dose is off target and less than 50 ÂµM peak concentration. The optimal dose is&#xD;
      defined as the dose at which at least 5 of 6 patients achieve optimal plasma concentrations&#xD;
      of suramin and no more than 1 of 6 patients experiences dose-limiting toxicity. In the event&#xD;
      of dose-limiting toxicity, doses of docetaxel and gemcitabine are adjusted until the optimal&#xD;
      dose in combination with suramin is determined.&#xD;
&#xD;
      Patients are followed for at least 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of suramin, graded according to the revised NCI CTC version 2.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose of chemotherapy, defined as the dose at which no more than 1/6 patients develop DLT graded according to the revised NCI CTC version 2.0</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30 minutes on days 1 and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suramin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>309 F</other_name>
    <other_name>Antrypol</other_name>
    <other_name>Bayer 205</other_name>
    <other_name>Fourneau 309</other_name>
    <other_name>Germanin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Stage IIIB* or IV&#xD;
&#xD;
          -  Progressive disease after prior platinum-containing regimen (e.g., cisplatin,&#xD;
             carboplatin, or oxaliplatin)&#xD;
&#xD;
          -  No known brain or leptomeningeal disease, unless all of the following are true:&#xD;
&#xD;
               -  Lesions were previously irradiated&#xD;
&#xD;
               -  No concurrent corticosteroids&#xD;
&#xD;
               -  No clinical symptoms&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure requiring therapy&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active serious infectious process&#xD;
&#xD;
          -  No grade 2 or greater neuropathy&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No psychiatric disorder that would preclude giving informed consent or interfere with&#xD;
             study follow-up&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior cytotoxic chemotherapy and recovered&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
          -  No prior gemcitabine&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
          -  At least 2 weeks since prior epidermal growth factor receptor therapy&#xD;
&#xD;
          -  Prior suramin allowed&#xD;
&#xD;
          -  No concurrent anti-HIV medications for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Villalona-Calero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Suramin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

